菜单

Global Compliance without the Costly Infrastructure

WuXi Biologics provides global biosafety testing powered by advanced technologies, over 400 experts, and a proven regulatory track record. From cell bank characterization through unprocessed bulk (UPB) testing, we deliver compliant, cost-effective solutions—without the need for your own Biosafety Level 2 (BSL-2) or GMP facilities. Competitive pricing, robust IP protection, and scientific expertise clear BLA, IND, and other milestones.

Learn More Now

Our full suite of biosafety testing services includes

, single-use technology, and Ambr high-throughput systems accelerate modeling and variability testing.

allow parallel purification development with automated control, eliminating downstream delays.

enable high-throughput impurity and CQA profiling.

ensure rapid, sensitive analysis of charge variants and purity.

(80% with advanced degrees) adapt programs in real-time to meet evolving technical and regulatory needs.

, single-use technology, and Ambr high-throughput systems accelerate modeling and variability testing.

allow parallel purification development with automated control, eliminating downstream delays.

enable high-throughput impurity and CQA profiling.

ensure rapid, sensitive analysis of charge variants and purity.

(80% with advanced degrees) adapt programs in real-time to meet evolving technical and regulatory needs.

Our biosafety testing spans the full development lifecycle, ensuring safe, compliant outcomes at every stage.

Comprehensive Biosafety Testing in Expert Hands

Our biosafety labs in Suzhou, China and nearby Shanghai Lingang have set the standard in Asia since 2015. Today, hubs in the US, Europe, and Singapore—unified by centralized program management—extend our capabilities worldwide. Half of more than 1,000 regulatory filings are in the US and Europe.

Twelve labs for viral clearance studies, each supported by rigorous data integrity systems, safeguard program confidentiality. Optional remote services reduce operational burdens without slowing timelines.

Service Activity

Turnaround Time

Viral clearance studies for IND and BLA filing

2 to 3 months

Clinical UBP testing

~6 weeks

Commercial UPB release testing

~35 days

Master cell bank characterization

11 weeks

Working cell bank characterization

9 weeks

End of production cells characterization

9 weeks

BSL-2 and GMP Labs with Immediate Capacity

Our biosafety labs in Suzhou, China and nearby Shanghai Lingang have set the standard in Asia since 2015. Today, hubs in the US, Europe, and Singapore—unified by centralized program management—extend our capabilities worldwide. Half of more than 1,000 regulatory filings are in the US and Europe.

Spanning over 24,000 square meters, the labs provide the scale and flexibility to meet ambitious timelines. Our record exceeds 460 successful audits from clients and agencies including FDA, EMA, PMDA, TGA, Health Canada, and NMPA, demonstrating strong quality systems. We have also passed 44 EU qualified person audits.

Antibiotic-Free Cell Selection

In 2024, FDA recognized the outcome of an EMA GMP inspection under the US-EU Mutual Recognition Agreement, reducing regulatory risk for US clients. Additional certifications include:

  • EMA GMP certification
  • FDA Remote Regulatory Assessment
  • TGA and Health Canada GMP Clearance
  • PMDA GMP completion notification
  • CNAS accreditation

Services Essential to Regulatory Enablement

Cryo-Transmission Electron Microscopy

Cryo-transmission electron microscopy (cryo-TEM) preserves biomolecules in a near-native state, enabling structural insights at atomic or near-atomic resolution. WuXi Biologics leverages cryo-TEM to characterize viral vectors, nanoparticles, and biological macromolecules, providing critical quality attributes that support research and regulatory objectives.

Fully GLP- and GMP-compliant, our cryo-TEM service requires as little as 3 μL of sample per grid and supports diverse applications. Automated data processing yields high-resolution insights that accelerate development and strengthen biologic quality.

Applications

Characterization Attributes

Adeno-associated virus (AAV), lentivirus, virus-like particles, and adenovirus

Assess morphology, size distribution, full/empty capsid ratio, particle size, aggregation, structural integrity, and 3D structure.

Lipid nanoparticles, liposomes, and extracellular vesicles

Characterize morphology, size distribution, membrane thickness, lamellarity, and drug encapsulation.

Proteins, antibodies, membrane proteins, antibody-drug conjugates, and vaccines

Elucidate complex assembly, conformational states, interaction interfaces, and epitope mapping.

Cell Bank Characterization

A contamination-free, well-characterized cell bank is essential to the safety, consistency, and scalability of biologics. WuXi Biologics provides comprehensive characterization services across all critical tiers to ensure identity, purity, and stability as your product advances toward commercialization.

Viral Clearance Studies

From preclinical through IND and BLA submissions, viral clearance studies are essential to biologic development. WuXi Biologics offers unmatched scientific expertise and global regulatory experience. Since 2015, we have completed more than 1,600 viral clearance studies filed with FDA, EMA, NMPA, PMDA, TGA, and other agencies.

Our team partners with clients align protocols with downstream purification strategies and regulatory expectations. Supported by a robust process database, we can anticipate viral inactivation and removal rates across purification steps, reducing redundant work, shortening timelines, and controlling project costs.

Our expertise spans tissue-based medical devices and a wide range of biologic modalities:

Download the Service Sheet

Unprocessed Bulk Release Testing

Per ICH Q5A and other global guidelines, each batch of cell harvest material or UPB must be tested for the presence of adventitious virus and mycoplasma. WuXi Biologics offers cultivation-based and molecular biology approaches—such as qPCR—alongside US, European, Japanese, and Chinese Pharmacopeia methods under GLP and GMP standards.

Our streamlined testing and quality assurance processes ensure reliable lot release with rapid reporting. To date, we have supported the release of over 6,800 clinical and commercial batches without any delivery days. Expedited turnaround times are available to meet manufacturing schedules.

Raw Material Risk Evaluation

Animal-derived materials used in cell line development or manufacturing increase the risk of adventitious contamination. WuXi Biologics reduces the risk through comprehensive biosafety testing of raw materials such as media and serums, including:

  • Sterility
  • Bioburden
  • Mycoplasma
  • Adventitious testing for animal-derived components
  • Adventitious testing for animal-derived components
    • 9CRF porcine and bovine tests required by USDA
    • PCR-based tests for specific viruses (eg, porcine circovirus types 1 and 2, bovine polyomavirus)

Related Resources

[Service Sheet] Viral Clearance Studies

Download Now

[Flyer] Biosafety Testing

Download Now

[Video] Biosafety Risk Mitigation Plan Overview – Two-Minute Tuesday Technical Training

Watch Now

Connect with our Experts

Let’s discuss your project needs.
Contact Us